W
WAVEMAN · COMPANY
BBIO · Bridgebio Pharma, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

BBIO

BridgeBio Pharma, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001743881
CONGRESS · 1FORM 144 · 10☆ WATCH
INSIDER NET · 180D
-$50.5M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
1
FUNDS ADDED · QTR
260
13F, latest reported quarter
REVENUE GROWTH
+126.3%
XBRL, annual
NET MARGIN
-146.0%
CONVERSIONS · 180D
19
codes C/M, not in net · $5.8M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$50.5M over 180 days
-$27.6M over 90 days
below 94% of Pharma & Biotech
CONGRESS
1 member bought in the last year
the lowest in Pharma & Biotech
FUNDS
260 funds added or opened last quarter
more than 91% of Pharma & Biotech
REVENUE
+126.3% year over year
more than 87% of Pharma & Biotech
MARGIN
-146.0% net margin
below 69% of Pharma & Biotech
BUYBACKS
$210.0M repurchased, FY to 2026-06-30
more than 79% of Pharma & Biotech
SHORT
11.9% of shares outstanding short · 11.5 days to cover · settled 2026-07-31
more than 83% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$50.5M across 7 people in 180 days.
260 funds added or opened positions in the latest 13F quarter, of 482 holders.
1 member of Congress reported buying it this year.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +49.7%
+49.7%12M
-2%+25%+53%+80%2025-092025-102025-122026-032026-052026-072026-09 2026-07-09 · Cook Jennifer E. sold $10.1M2025-10-29 · MCCORMICK FRANK sold $7.3M2026-06-15 · Cook Jennifer E. sold $5.9M2026-03-04 · Ellis Andrea sold $4.2M2025-09-05 · MCCORMICK FRANK sold $3.9M2025-11-06 · DANIELS RONALD J sold $3.9M2026-07-09 · Cook Jennifer E. sold $3.0M2025-10-29 · MCCORMICK FRANK sold $3.0M2026-06-24 · Cook Jennifer E. sold $2.6M2025-11-17 · Lo Andrew sold $2.5M2025-12-15 · Kumar Neil sold $2.1M2025-10-29 · MCCORMICK FRANK sold $2.1M2025-11-18 · Lo Andrew sold $2.0M2025-11-12 · Valantine Hannah sold $1.7M2025-11-18 · Lo Andrew sold $1.6M2026-04-10 · Kumar Neil sold $1.5M2026-07-09 · Ellis Andrea sold $1.4M2026-08-18 · Kumar Neil sold $1.4M2026-02-19 · Kumar Neil sold $1.3M2026-08-18 · Kumar Neil sold $1.2M2025-10-09 · Kumar Neil sold $1.1M2026-06-04 · Kumar Neil sold $1.1M2026-02-10 · Kumar Neil sold $1.0M2026-02-10 · Kumar Neil sold $1.0M2026-02-17 · Trimarchi Thomas sold $1.0M2026-03-12 · Kumar Neil sold $981.8K2026-02-27 · Valantine Hannah sold $978.3K2026-03-12 · Kumar Neil sold $950.7K2025-11-20 · Kumar Neil sold $942.3K2026-05-08 · Kumar Neil sold $931.4K2026-05-08 · Kumar Neil sold $931.3K2025-12-05 · Kumar Neil sold $914.4K2025-12-04 · Kumar Neil sold $907.9K2025-12-04 · Kumar Neil sold $907.3K2025-09-05 · Kumar Neil sold $898.4K2025-12-05 · Kumar Neil sold $897.5K2025-09-05 · Kumar Neil sold $893.1K2026-01-08 · Kumar Neil sold $851.8K2026-01-08 · Kumar Neil sold $848.0K2026-01-09 · Kumar Neil sold $827.0K2026-01-09 · Kumar Neil sold $816.4K2026-05-21 · Kumar Neil sold $792.9K2026-08-19 · KUMAR HALDEA FAMILY IRREVOCABLE TRU/T/A DTD 05/18/2019 filed to sell $2.5M2026-08-18 · NEIL KUMAR filed to sell $2.8M2026-08-17 · RANDAL SCOTT filed to sell $1.7M2026-07-09 · ANDREA ELLIS filed to sell $1.4M2026-07-09 · JENNIFER COOK filed to sell $13.2M2026-06-24 · JENNIFER COOK filed to sell $2.6M2026-06-24 · RANDAL SCOTT filed to sell $150.7K2026-06-23 · HANNAH A VALANTINE filed to sell $150.6K2026-06-23 · JENNIFER COOK filed to sell $150.6K2026-06-22 · HANNAH A VALANTINE filed to sell $190.9K
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $50.5M sold by insiders over 180 days, 260 funds added last quarter, 1 Congress member(s) bought in 12 months, $24.8M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, BridgeBio Pharma, Inc. insiders sold a net $50.5M of stock across 279 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Kumar Neil
Chief Executive Officer
SELL
2026-08-19
8,100.0
$679.3K
Kumar Neil
Chief Executive Officer
SELL
2026-08-19
1,800.0
$152.4K
Kumar Neil
Chief Executive Officer
SELL
2026-08-19
100.0
$8.6K
Kumar Neil
Chief Executive Officer
SELL
2026-08-18
1,900.0
$154.2K
Kumar Neil
Chief Executive Officer
SELL
2026-08-18
17,279.0
$1.4M
279 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 274 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Jupiter Topco LLC
14,110,278.0 sh
$1.1B
Kohlberg Kravis Roberts & Co. L.P.
13,260,971.0 sh
$987.7M
FARALLON CAPITAL MANAGEMENT, L.L.C.
10,743,063.0 sh
$800.1M
BlackRock, Inc.
10,287,156.0 sh
$766.2M
VIKING GLOBAL INVESTORS LP
9,949,219.0 sh
$741.0M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
KUMAR HALDEA FAMILY IRREVOCABLE TRU/T/A DTD 05/18/2019
FILED 2026-08-19
$2.5M
NEIL KUMAR
FILED 2026-08-18
$2.8M
RANDAL SCOTT
FILED 2026-08-17
$1.7M
ANDREA ELLIS
FILED 2026-07-09
$1.4M
JENNIFER COOK
FILED 2026-07-09
$13.2M
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Tema Oncology ETF
$7.6M POSITION · AS OF 2026-02-28
4.8%
Franklin Genomic Advancements ETF
$905.4K POSITION · AS OF 2026-03-31
4.2%
TETON Convertible Securities Fund
$339.6K POSITION · AS OF 2026-03-31
3.0%
Franklin Convertible Securities Fund
$76.3M POSITION · AS OF 2026-04-30
2.6%
F/m Emerald Life Sciences Innovation ETF
$2.5M POSITION · AS OF 2026-02-28
2.6%
SIMT Small Cap Growth Fund
$6.6M POSITION · AS OF 2026-03-31
2.4%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Corporate PAC
FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors
Bridgebio Pharma Inc. Pac (Bridgebiopac)
CYCLE 2026 · $35K SPENT
$129.9K
FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION
Executive pay vs shareholder return · Dr. Kumar
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2023
$12.2M
$70.1M
$6.7M
+15%
+19%
2022
$6.7M
-$11.3M
$3.0M
-78%
+14%
2021
$25.6M
-$132.8M
$8.7M
-52%
+26%
2020
$10.1M
$151.1M
$4.8M
+103%
+26%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$502.1M$221.9M$9.3M$77.6M
OPERATING INCOME$-523.4M$-593.0M$-607.4M$-512.2M
NET INCOME$-732.9M$-543.3M$-653.3M$-484.6M
EPS (DILUTED)-3.78-2.88-3.95-3.26
OPERATING CASH FLOW$-445.9M$-520.7M$-527.7M$-419.5M
CASH$570.1M$681.1M$375.9M$376.7M
LONG-TERM DEBT$2.0B$437.3M$446.4M$431.0M
BUYBACKS$48.3M$0$0$0
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →